Sorensen Erik N, Griffith Bartley P, Feller Erika D, Kaczorowski David J
Division of Perioperative Services, University of Maryland Medical Center, Baltimore, Maryland.
Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore, Maryland.
J Card Surg. 2020 Jul;35(7):1539-1547. doi: 10.1111/jocs.14655. Epub 2020 Jun 24.
Despite improved survival and morbidity after durable left ventricular assist device (dLVAD), outcomes for cardiogenic shock patients are suboptimal. Temporary mechanical circulatory support (tMCS) can permit optimization before dLVAD. Excellent outcomes have been observed using minimally-invasive dLVAD implantation. However, some feel tMCS contraindicates this approach. To evaluate whether left thoracotomy/hemisternotomy (LTHS) dLVAD placement is safe in this setting, we compared patients who did and did not require tMCS.
Outcomes for patients receiving dLVADs via LTHS were compared among those bridged with extracorporeal membrane oxygenation (ECMO), intra-aortic balloon pump (IABP), or no tMCS. We evaluated demographics, comorbidities, laboratory and hemodynamic data, and intraoperative and postoperative outcomes.
Eighty-three patients underwent LTHS dLVAD placement. Fifty did not require tMCS, while 22 (26%) required IABP, and 11 (13%) ECMO. Non-tMCS patients were primarily Intermacs 3 (56%), while IABP recipients were mainly Intermacs 2 (45%). All patients with ECMO were Intermacs 1. Patients with tMCS had worse end-organ function. Operative outcomes were similar except more concomitant procedures and red-cell transfusions in patients with ECMO. Intensive care unit and hospital length of stay and inotrope duration were also similar. There were no differences in bleeding, stroke, and infection rates. Three- and 12-month survival were: no tMCS: 94%, 86%; IABP: 100%, 88%; and ECMO: 81%, 81% (P = .45).
Patients with cardiogenic shock can safely undergo LTHS dLVAD implantation after stabilization with ECMO or IABP. Outcomes and complications in these patients were comparable to a less severely ill cohort without tMCS.
尽管持久左心室辅助装置(dLVAD)植入后患者生存率提高、发病率降低,但心源性休克患者的治疗效果仍不理想。临时机械循环支持(tMCS)可在植入dLVAD前使病情达到最佳状态。采用微创dLVAD植入术已观察到良好的治疗效果。然而,有些人认为tMCS是这种方法的禁忌证。为评估在这种情况下左胸廓切开术/半胸骨切开术(LTHS)植入dLVAD是否安全,我们比较了需要和不需要tMCS的患者。
比较了通过LTHS植入dLVAD的患者,这些患者分别采用体外膜肺氧合(ECMO)、主动脉内球囊反搏(IABP)或未使用tMCS进行过渡。我们评估了人口统计学、合并症、实验室和血流动力学数据以及术中和术后结果。
83例患者接受了LTHS植入dLVAD。50例患者不需要tMCS,22例(26%)需要IABP,11例(13%)需要ECMO。未使用tMCS的患者主要为Intermacs 3级(56%),而接受IABP的患者主要为Intermacs 2级(45%)。所有接受ECMO的患者均为Intermacs 1级。使用tMCS的患者终末器官功能较差。手术结果相似,但接受ECMO的患者有更多的同期手术和红细胞输注。重症监护病房和住院时间以及血管活性药物使用时间也相似。出血、中风和感染率无差异。3个月和12个月生存率分别为:未使用tMCS:94%,86%;IABP:100%,88%;ECMO:81%,81%(P = 0.45)。
心源性休克患者在通过ECMO或IABP稳定病情后可安全地接受LTHS植入dLVAD。这些患者的治疗效果和并发症与未使用tMCS的病情较轻的队列相当。